Business Wire

H.I.G. Europe to Acquire KPMG’s UK Restructuring Business, Rebranded to Interpath Advisory

Share

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce that one of its affiliates has signed a definitive agreement to acquire KPMG’s UK restructuring business, a leading provider of insolvency, financial restructuring and turnaround services in the UK and globally. Terms of the transaction, which is expected to complete in April 2021, were not disclosed.

KPMG UK Restructuring is a leading multidisciplinary practice of approximately 22 partners and 528 staff located across the full breadth of the UK. The group advises companies, lenders, equity holders and a wide range of other stakeholders including Government, regulators and pension trustees to navigate through the issues associated with economic disruption and overcome financial and operational challenges.

Following completion of the transaction, the business will rebrand to Interpath Advisory, becoming the largest independent restructuring and turnaround team in the UK. The new business will be led by Blair Nimmo, Will Wright and Mark Raddan, who have also led the transaction as three of the senior partners in KPMG’s UK Restructuring practice. They will be supported by an experienced group of partners who will remain as significant shareholders in the business.

H.I.G.’s investment will support Interpath Advisory in its transition to an independent business and strengthen its existing capabilities as it continues to grow its advisory offering in the UK and beyond. H.I.G. has a successful international track record of investing in and supporting the long-term growth of consulting and professional services businesses across Europe and the US.

Blair Nimmo said: “This is tremendously exciting news for our business and our people and opens up enormous potential for growth. With over 500 people based across the full breadth of the UK, Interpath Advisory will become the largest independent restructuring and turnaround business in the country. From the strong foundations that we’ve built over the past 50 years, we’re looking forward to building a market-leading international advisory business that is capable of servicing the largest and most complex engagements.”

Markus Noe-Nordberg, Managing Director and Head of the H.I.G. European Middle Market LBO team, which led the transaction, commented: “We are thrilled to welcome Interpath Advisory to the H.I.G. family. H.I.G. has had great success investing in leading professional services firms, and we will use this experience to help Interpath maximise its potential. This transaction is an ideal fit with our investment mandate and underscores once more H.I.G.’s ability to execute on complex transactions such as carve-outs.”

Nishant Nayyar, Managing Director at H.I.G. Europe, added: “We have been impressed by Interpath's track record, deep client relationships and above all its collaborative culture. Interpath will be ideally positioned to support its clients in their recovery from the disruptions caused by the COVID-19 pandemic. We are proud to partner with Blair, Mark, Will and the entire team and look forward to supporting Interpath's continued growth.”

About H.I.G. Capital

H.I.G. is a leading global alternative assets investment firm with over €35 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Rio de Janeiro, São Paulo and Bogotá, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:

  1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €27 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Contact information

Markus Noe-Nordberg
Managing Director
mnordberg@higcapital.com

Nishant Nayyar
Managing Director
nnayyar@higcapital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coded Agency Celebrates Continued Growth with Rebrand, Internal Promotions and Client Wins14.4.2021 17:00:00 EEST | Press release

Global modern communications company Coded Agency today announces a highly-anticipated, strategic overhaul of its branding and website following steady growth and innovation into new markets and industries. Coded Agency, formerly known as codedpr, was founded in 2015 and quickly grew to become a leading agency of record for a range of lifestyle, fashion, beauty, fitness and wellness brands. In 2020, the agency generated a net income increase of 35%, despite an unprecedented global pandemic. Its upward trajectory continues in 2021 with not only a 65% increase in revenue in Q1 and a 50% increase in clients between Q1 and Q2, but a bold, fresh new look, instrumental employee promotions and expansion into Europe with the agency founder’s relocation to France. The minority-owned, female-founded company renews its namesake as Coded Agency in tandem with a new website and branding designed by Designsake Studio, a San Francisco-based, award-winning and female founded design firm. “Coded Agency

Microsoft Azure Customers Now Able to Acquire beqom with Existing Azure Credit14.4.2021 16:20:00 EEST | Press release

beqom, provider of cloud-based compensation management software, announced that Microsoft has designated beqom as an eligible “Microsoft Transact” application for customers of the Microsoft Azure cloud platform. This means that Azure customers can use their existing Azure budget commitment to fund the purchase of the beqom compensation management solution. “This presents a huge opportunity for Azure customers,” says Francois D’Haegeleer, beqom Head of Business Development. “As an eligible application, if you purchase beqom directly through the Azure Marketplace, Microsoft will contribute 100% of qualifying offer purchases towards your organization’s Azure consumption commitment at each invoice period, including software/IP costs. So you can get beqom’s world-class compensation management platform, used by Global 2000 companies around the world, for no additional budget outlay.” “Our enterprise customers want to streamline their software procurement process,” says Andrew Reid, Microsoft

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer14.4.2021 16:00:00 EEST | Press release

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies. Under the new agreement, joint research will continue for five additional years. “Our collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an import

University of Siena Researchers Demonstrate Rapid UV Disinfection of Operating Rooms Between Surgeries14.4.2021 15:00:00 EEST | Press release

UltraViolet Devices, Inc. (UVDI), a global leader in Ultraviolet Air and Surface disinfection, announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at the Society for Healthcare Epidemiology of America (SHEA) Spring Conference, taking place April 13-16, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005184/en/ In the University of Siena research, the UVDI-360 Room Sanitizer effectively inactivated germs in operating rooms in six minutes. (Photo: Business Wire) In the research, conducted by Dr. Gabriele Messina, Professor of Public Health, University of Siena at the Rugani Hospital Monteriggioni in Siena, the UVDI-360 Room Sanitizer achieved a greater than 97% germ reduction in operating rooms in only six minutes, with two three-minute disinfection cycles run on each side of the operating table. Testing the UVDI-360 R

Amylyx Pharmaceuticals Provides Global Regulatory Update on AMX0035 for ALS14.4.2021 15:00:00 EEST | Press release

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of ALS. The company intends to submit a Marketing Authorization Application (MAA) for AMX0035 to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) by the end of 2021. As previously reported, the company plans to submit a marketing application with Health Canada Q2 2021. The FDA has expressed an interest in seeing data from an additional placebo-controlled clinical trial prior to receiving a New Drug Application (NDA), the vehicle through which a pharmaceutical sponsor formally proposes that the FDA approve an investigational product. To fulfill the FDA’s request and to continue to build upon the growing body of evidence supporting AMX0035 for

Noxopharm Files Septic Shock Treatment Patent for Veyonda®14.4.2021 15:00:00 EEST | Press release

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses. Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock. Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response

HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools14.4.2021 13:00:00 EEST | Press release

HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/ HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of h

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom